Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn’s disease

References

• Ronald AR, Nicolle LE, Stamm E, et al. Urinary tract infection in adults: research priorities and strategies. Int J Antimicrob Agents. 2001;17(4):343–348.
   PubMed Web of Science ®Google Scholar
• Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health. 1990;80(3):331–333.
   PubMed Web of Science ®Google Scholar
• Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1–13.
   PubMed Web of Science ®Google Scholar
• Griebling TL. Urinary tract infection in women. In: Litwin MS, Saigal CS, Editors. Urologic diseases in America. Washington (DC): In US Government Printing Office; 2007. p. 587–620.
   Google Scholar
• Sanchez GV, Master RN, Bordon J. Trimethoprim-sulfamethoxazole may no longer be acceptable for the treatment of acute uncomplicated cystitis in the United States. Clin Infect Dis. 2011;53(3):316–317.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Hoban DJ, Decorby MR, et al. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother. 2006;50(6):2251–2254.
   PubMed Web of Science ®Google Scholar
• Zhanel G, Hisanaga T, Laing N, et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Ag. 2006;27(6):468–475.
   PubMed Web of Science ®Google Scholar
• Schaeffer A. The expanding role of fluoroquinolones. Disease-a-month. 2003;49(2):129–147.
   PubMed Web of Science ®Google Scholar
• Dielubanza E, Schaeffer A. Urinary tract infections in women. Med Clin Am. 2011;95(1):27–41.
   PubMed Web of Science ®Google Scholar
• Cole ST. Who will develop new antibacterial agents? Philos Trans Royal Soc B: Biol Sci. 2014;369(1645):20130430.
   PubMed Web of Science ®Google Scholar
• Nathan C. Fresh approaches to anti-infective therapies. Sci Transl Med. 2012;4(140):140sr2.
   PubMed Web of Science ®Google Scholar
• Lee YM, Almqvist F, Hultgren SJ. Targeting virulence for antimicrobial chemotherapy. Curr Opin Pharmacol. 2003;3(5):513–519.
   PubMed Web of Science ®Google Scholar
• Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov. 2010;9(2):117–128.
   PubMed Web of Science ®Google Scholar
• Garland M, Loscher S, Bogyo M. Chemical strategies to target bacterial virulence. Chem Rev. 2017;117(5):4422–4461. .
   PubMed Web of Science ®Google Scholar
• Cozens D, Read RC. Anti-adhesion methods as novel therapeutics for bacterial infections. Expert Rev Anti Infect Ther. 2012;10(12):1457–1468.
   PubMed Web of Science ®Google Scholar
• McGann P, Snesrud E, Maybank R, et al. Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF plasmid: first report of mcr-1 in the United States. Antimicrob Agents Chemother. 2016;60(7):4420–4421.
   PubMed Web of Science ®Google Scholar
• Mediavilla JR, Patrawalla A, Chen L, et al. Colistin- and carbapenem-resistant Escherichia coli harboring mcr-1 and blaNDM-5, causing a complicated urinary tract infection in a patient from the United States. mBio. 2016;7(4):e01191–01116.
   PubMed Web of Science ®Google Scholar
• Snyder J, Lloyd A, Lockatell C, et al. Role of phase variation of type 1 fimbriae in a uropathogenic Escherichia coli cystitis isolate during urinary tract infection. Infect Immun. 2006;74(2):1387–1393.
   PubMed Web of Science ®Google Scholar
• Wu XR, Sun TT, Medina JJ. In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. Proc Natl Acad Sci USA. 1996;93(18):9630–9635.
   PubMed Web of Science ®Google Scholar
• Anderson GG, Palermo JJ, Schilling JD, et al. Intracellular bacterial biofilm-like pods in urinary tract infections. Science. 2003;301(5629):105–107.
   PubMed Web of Science ®Google Scholar
• Zhou G, Mo WJ, Sebbel P, et al. Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. J Cell Sci. 2001;114(Pt 22):4095–4103.
   PubMed Web of Science ®Google Scholar
• Dorta DA, Sivignon A, Chalopin T, et al. The antiadhesive strategy in Crohn’s disease: orally active mannosides to decolonize pathogenic Escherichia coli from the gut. Chembiochem. 2016;17(10):936–952.
   PubMed Web of Science ®Google Scholar
• Duguid JP, Gillies RR. Fimbriæ and adhesive properties in dysentery bacilli. J Path Bact. 1957;74(2):397–411.
   Google Scholar
• Ofek I, Mirelman D, Sharon N. Adherence of Escherichia coli to human mucosal cells mediated by mannose receptors. Nature. 1977;265:623–625.
   PubMed Web of Science ®Google Scholar
• Aronson M, Medalia O, Schori L, et al. Prevention of colonization of the urinary tract of mice with Escherichia coli by blocking of bacterial adherence with methyl a-D-mannopyranoside. J Infect Dis. 1979;139:329–332.
   PubMed Web of Science ®Google Scholar
• Firon N, Ofek I, Sharon N. Interaction of mannose-containing oligosaccharides with the fimbrial lectin of Escherichia coli. Biochem Biophys Res Commun. 1982;105(4):1426–1432.
   PubMed Web of Science ®Google Scholar
• Firon N, Ofek I, Sharon N. Carbohydrate specificity of the surface lectins of Escherichia coli, Klebsiella pneumoniae, and Salmonella typhimurium. Carb Res. 1983;120:235–249.
   PubMed Web of Science ®Google Scholar
• Firon N, Ashkenazi S, Mirelman D, et al. Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells. Infect Immun. 1987;55(2):472–476.
   PubMed Web of Science ®Google Scholar
• Andrade JRC. Role of fimbrial adhesiveness in experimental guinea pig kerato conjunctivitis by shigella flexneri. Rev Microbiol. 1980;11(4):117–125.
   Google Scholar
• Neeser J, Koellreutter B, Wuersch P. Oligomannoside-type glycopeptides inhibiting adhesion of Escherichia coli strains mediated by type 1 pili: preparation of potent inhibitors from plant glycoproteins. Infect Immun. 1986;52(4):428–436.
   PubMed Web of Science ®Google Scholar
• Mydock-McGrane LK, Cusumano ZT, Janetka JW. Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn’s disease. Expert Opin Ther Pat. 2016;26(2):175–197.
   PubMed Web of Science ®Google Scholar
• Klein T, Abgottspon D, Wittwer M, et al. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem. 2010;53(24):8627–8641.
   PubMed Web of Science ®Google Scholar
• Rabbani S, Jiang X, Schwardt O, et al. Expression of the carbohydrate recognition domain of FimH and development of a competitive binding assay. Anal Biochem. 2010;407(2):188–195.
   PubMed Web of Science ®Google Scholar
• Lindhorst TK, Kotter S, Krallmann-Wenzel U, et al. Trivalent alpha-D-mannoside clusters as inhibitors of type-1 fimbriae-mediated adhesion of Escherichia coli: structural variation and biotinylation. J Chem Soc Perkin Trans I. 2001;8:823–831.
   Google Scholar
• Brument S, Sivignon A, Dumych TI, et al. Thiazolylaminomannosides as potent antiadhesives of type 1 piliated Escherichia coli isolated from Crohn’s disease patients. J Med Chem. 2013;56(13):5395–5406.
   PubMed Web of Science ®Google Scholar
• Chalopin T, Dorta DA, Sivignon A, et al. Second generation of thiazolylmannosides, FimH antagonists for E. coli-induced Crohn’s disease. Org Biomol Chem. 2016;14(16):3913–3925.
   PubMed Web of Science ®Google Scholar
• Han Z, Pinkner JS, Ford B, et al. Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem. 2010;53(12):4779–4792.
   PubMed Web of Science ®Google Scholar
• Kleeb S, Pang L, Mayer K, et al. FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile. J Med Chem. 2015;58(5):2221–2239.
   PubMed Web of Science ®Google Scholar
• Bouckaert J, Berglund J, Schembri M, et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol. 2005;55(2):441–455.
   PubMed Web of Science ®Google Scholar
• Pang L, Kleeb S, Lemme K, et al. FimH antagonists: structure-activity and structure-property relationships for biphenyl alpha-D-mannopyranosides. ChemMedChem. 2012;7(8):1404–1422.
   PubMed Web of Science ®Google Scholar
• Han Z, Pinkner JS, Ford B, et al. Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J Med Chem. 2012;55(8):3945–3959.
   PubMed Web of Science ®Google Scholar
• Kranz JK, Schalk-Hihi C. Protein thermal shifts to identify low molecular weight fragments. Methods Enzymol. 2011;493:277–298.
   PubMed Web of Science ®Google Scholar
• Niesen F, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc. 2007;2(9):2212–2221.
   PubMed Web of Science ®Google Scholar
• Hultgren S, Schwan W, Schaeffer A, et al. Regulation of production of type 1 pili among urinary tract isolates of Escherichia coli. Infect Immun. 1986;54(3):613–620.
   PubMed Web of Science ®Google Scholar
• Mydock-McGrane L, Cusumano Z, Han Z, et al. Antivirulence C-mannosides as antibiotic-sparing, oral therapeutics for urinary tract infections. J Med Chem. 2016;59:9390–9408.
   PubMed Web of Science ®Google Scholar
• Jarvis C, Han Z, Kalas V, et al. Antivirulence isoquinolone mannosides: optimization of the biaryl aglycone for FimH lectin binding affinity and efficacy in the treatment of chronic UTI. ChemMedChem. 2016;11(4):367–373.
   PubMed Web of Science ®Google Scholar
• Abgottspon D, Rölli G, Hosch L, et al. Development of an aggregation assay to screen FimH antagonists. J Microbiol Methods. 2010;82:249–255.
   PubMed Web of Science ®Google Scholar
• O’Toole G, Kolter R. Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis. Mol Microbiol. 1998;28(3):449–461.
   PubMed Web of Science ®Google Scholar
• Cegelski L, Pinkner J, Hammer N, et al. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol. 2009;5(12):913–919.
   PubMed Web of Science ®Google Scholar
• Pinkner JS, Remaut H, Buelens F, et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci USA. 2006;103(47):17897–17902.
   PubMed Web of Science ®Google Scholar
• Blango MG, Mulvey MA. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother. 2010;54(5):1855–1863.
   PubMed Web of Science ®Google Scholar
• Scharenberg M, Abgottspon D, Cicek E, et al. A flow cytometry-based assay for screening FimH antagonists. Assay Drug Dev Technol. 2011;9(5):455–464.
   PubMed Web of Science ®Google Scholar
• Kalas V, Pinkner JS, Hannan TJ, et al. Evolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions. Sci Adv. 2017;3(2):e1601944.
   PubMed Web of Science ®Google Scholar
• Eris D, Preston RC, Scharenberg M, et al. The conformational variability of FimH: which conformation represents the therapeutic target? Chembiochem. 2016;17(11):1012–1020.
   PubMed Web of Science ®Google Scholar
• Sauer MM, Jakob RP, Eras J, et al. Catch-bond mechanism of the bacterial adhesin FimH. Nat Commun. 2016;7:10738.
   PubMed Web of Science ®Google Scholar
• Hannan TJ, Mysorekar IU, Hung CS, et al. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. Plos Pathog. 2010;6(8):e1001042.
   PubMed Web of Science ®Google Scholar
• Hannan TJ, Totsika M, Mansfield KJ, et al. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev. 2012;36(3):616–648.
   PubMed Web of Science ®Google Scholar
• Hung CS, Dodson KW, Hultgren SJ. A murine model of urinary tract infection. Nat Protoc. 2009;4(8):1230–1243.
   PubMed Web of Science ®Google Scholar
• Justice SS, Hung C, Theriot JA, et al. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci USA. 2004;101(5):1333–1338.
   PubMed Web of Science ®Google Scholar
• Schwartz DJ, Conover MS, Hannan TJ, et al. Uropathogenic Escherichia coli superinfection enhances the severity of mouse bladder infection. Plos Pathog. 2015;11(1):e1004599.
   PubMed Web of Science ®Google Scholar
• Wright KJ, Seed PC, Hultgren SJ. Development of intracellular bacterial communities of uropathogenic Escherichia coli depends on type 1 pili. Cell Microbiol. 2007;9(9):2230–2241.
   PubMed Web of Science ®Google Scholar
• Cusumano CK, Pinkner JS, Han Z, et al. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med. 2011;3(109):109ra15.
   Web of Science ®Google Scholar
• Totsika M, Kostakioti M, Hannan TJ, et al. A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131. J Infect Dis. 2013;208(6):921–928.
   PubMed Web of Science ®Google Scholar
• Keane WF, Freedman LR. Pyelonephritis in normal mice produced by inoculation of E. coli into bladder lumen during water diuresis. Yale J Biol Med. 1967;40(3):231–237.
   PubMed Web of Science ®Google Scholar
• Murawski IJ, Maina RW, Malo D, et al. The C3H/HeJ inbred mouse is a model of vesico-ureteric reflux with a susceptibility locus on chromosome 12. Kidney Int. 2010;78(3):269–278.
   PubMed Web of Science ®Google Scholar
• Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al. Intercontinental emergence of Escherichia coli clone O25: H4-ST131producing CTX-M-15. J Antimicrob Chemother. 2008;61(2):273–281.
   PubMed Web of Science ®Google Scholar
• Barnich N, Carvalho FA, Glasser AL, et al. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest. 2007;117(6):1566–1574.
   PubMed Web of Science ®Google Scholar
• Carvalho FA, Barnich N, Sivignon A, et al. Crohn’s disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med. 2009;206(10):2179–2189.
   PubMed Web of Science ®Google Scholar
• Sivignon A, Yan X, Dorta DA, et al. Development of heptylmannoside-based glycoconjugate antiadhesive compounds against adherent-invasive Escherichia coli Bacteria associated with Crohn’s disease. mBio. 2015;6(6):e01298–e01215.
   PubMed Web of Science ®Google Scholar
• Kuehn MJ, Heuser J, Normark S, et al. P pili in uropathogenic E. coli are composite fibers with distinct fibrillar adhesive tips. Nature. 1992;356:252–255.
   PubMed Web of Science ®Google Scholar
• Sauer FG, Pinkner JS, Waksman G, et al. Chaperone priming of pilus subunits facilitates a topological transition that drives fiber formation. Cell. 2002;111:543–551.
   PubMed Web of Science ®Google Scholar
• Geibel S, Procko E, Hultgren SJ, et al. Structural and energetic basis of folded protein transport by the FimD usher. Nature. 2013;496:243–246.
   PubMed Web of Science ®Google Scholar
• Remaut H, Rose RJ, Hannan TJ, et al. Donor-strand exchange in chaperone-assisted pilus assembly proceeds through a concerted beta strand displacement mechanism. Mol Cell. 2006;22(6):831–842.
   PubMed Web of Science ®Google Scholar
• Sauer FG, Fütterer K, Pinkner JS, et al. Structural basis of chaperone function and pilus biogenesis. Science. 1999;285(5430):1058–1061.
   PubMed Web of Science ®Google Scholar
• Hung CS, Bouckaert J, Hung D, et al. Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Mol Microbiol. 2002;44(4):903–915.
   PubMed Web of Science ®Google Scholar
• Wellens A, Garofalo C, Nguyen H, et al. Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH oligomannose-3 complex. Plos One. 2008;3(4):e2040.
   PubMed Web of Science ®Google Scholar
• Chen SL, Hung CS, Pinkner JS, et al. Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding. Proc Natl Acad Sci USA. 2009;106(52):22439–22444.
   PubMed Web of Science ®Google Scholar
• Knight SD, Bouckaert J. Structure, function, and assembly of type 1 fimbriae. Top Curr Chem. 2009;288:67–107.
   PubMed Web of Science ®Google Scholar
• Bouckaert J, Mackenzie J, de Paz JL, et al. The affinity of the FimH fimbrial adhesin is receptor-driven and quasi-independent of Escherichia coli pathotypes. Mol Microbiol. 2006;61(6):1556–1568.
   PubMed Web of Science ®Google Scholar
• Wellens A, Lahmann M, Touaibia M, et al. The tyrosine gate as a potential entropic lever in the receptor-binding site of the bacterial adhesin FimH. Biochemistry. 2012;51:4790–4799.
   PubMed Web of Science ®Google Scholar
• Roos G, Wellens A, Touaibia M, et al. Validation of reactivity descriptors to assess the aromatic stacking within the tyrosine gate of FimH. Med Chem Lett. 2013;4:1085–1090.
   Web of Science ®Google Scholar
• Rabbani S, Krammer EM, Roos G, et al. Mutation of Tyr137 of the universal Escherichia coli fimbrial adhesin FimH relaxes the tyrosine gate prior to mannose binding. IUCrJ. 2017;4(1):7–23.
   PubMed Web of Science ®Google Scholar
• Sperling O, Fuchs A, Lindhorst TK. Evaluation of the carbohydrate recognition domain of the bacterial adhesin FimH: design, synthesis and binding properties of mannoside ligands. Org Biomol Chem. 2006;4(21):3913–3922.
   PubMed Web of Science ®Google Scholar
• Jiang X, Abgottspon D, Kleeb S, et al. Antiadhesion therapy for urinary tract infections – a balanced PK/PD profile proved to be key for success. J Med Chem. 2012;55(10):4700–4713.
   PubMed Web of Science ®Google Scholar
• Sharon N. Bacterial lectins, cell-cell recognition and infectious disease. FEBS Lett. 1987;217(2):145–157.
   PubMed Web of Science ®Google Scholar
• Fiege B, Rabbani S, Preston RC, et al. The tyrosine gate of the bacterial lectin FimH: a conformational analysis by NMR spectroscopy and X-ray crystallography. Chembiochem. 2015;16(8):1235–1246.
   PubMed Web of Science ®Google Scholar
• Grabosch C, Hartmann M, Schmidt-Lassen J, et al. Squaric acid monoamide mannosides as ligands for the bacterial lectin FimH: covalent inhibition or not? Chembiochem. 2011;12:1066–1074.
   PubMed Web of Science ®Google Scholar
• Schwardt O, Rabbani S, Hartmann M, et al. Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists. Bioorg Med Chem Lett. 2011;19(21):6454–6473.
   Web of Science ®Google Scholar
• Car Z, Hrenar T, Petrović Peroković VP, et al. Mannosylated N-aryl substituted 3-hydroxypyridine-4-ones: synthesis, hemagglutination inhibitory properties, and molecular modeling. Chem Biol Drug Des. 2014;84:393–401.
   PubMed Web of Science ®Google Scholar
• Tomašić T, Rabbani S, Gobec M, et al. Branched: a-D-mannopyranosides: a new class of potent FimH antagonists. Med Chem Commun. 2014;5(8):1247–1253.
   Web of Science ®Google Scholar
• Chandrasekaran V, Kolbe K, Beiroth F, et al. Synthesis and testing of the first azobenzene mannobioside as photoswitchable ligand for the bacterial lectin FimH. Beilstein J Org Chem. 2013;9:223–233.
   PubMed Web of Science ®Google Scholar
• Hartmann M, Papavlassopoulos H, Chandrasekaran V, et al. Inhibition of bacterial adhesion to live human cells: activity and cytotoxicity of synthetic mannosides. FEBS Lett. 2012;586:1459–1465.
   PubMed Web of Science ®Google Scholar
• Rodriguez VB, Kidd BA, Interlandi G, et al. Allosteric coupling in the bacterial adhesive protein FimH. J Biol Chem. 2013;288(33):24128–24139.
   PubMed Web of Science ®Google Scholar
• Yakovenko O, Tchesnokova V, Sokurenko EV, et al. Inactive conformation enhances binding function in physiological conditions. Proc Natl Acad Sci USA. 2015;112(32):9884–9889.
   PubMed Web of Science ®Google Scholar
• Feenstra T, Thogersen MS, Wieser E, et al. Adhesion of Escherichia coli under flow conditions reveals potential novel effects of FimH mutations. Eur J Clin Microbiol Infect Dis. 2017;36(3):467–478.
   PubMed Web of Science ®Google Scholar
• Szunerits S, Zagorodko O, Cogez V, et al. Differentiation of Crohn’s disease-associated isolates from other pathogenic Escherichia coli by fimbrial adhesion under shear force. Biology (Basel). 2016;5(2):14.
   Google Scholar
• Mockl L, Fessele C, Despras G, et al. En route from artificial to natural: evaluation of inhibitors of mannose-specific adhesion of E. coli under flow. Biochim Biophys Acta. 2016;1860(9):2031–2036.
   PubMed Web of Science ®Google Scholar
• Di L, Kerns EH. Profiling drug-like properties in discovery research. Curr Opin Chem Biol. 2003;7(3):402–408.
   PubMed Web of Science ®Google Scholar
• Ito S, Ando H, Ose A, et al. Relationship between the urinary excretion mechanisms of drugs and their physicochemical properties. J Pharm Sci. 2013;102(9):3294–3301.
   PubMed Web of Science ®Google Scholar
• de Ruyck J, Lensink MF, Bouckaert J. Structures of C-mannosylated anti-adhesives bound to the type 1 fimbrial FimH adhesin. IUCrJ. 2016;3(Pt 3):163–167.
   PubMed Web of Science ®Google Scholar
• Bennani YL, Cadilhac C, Das SK, et al. Mannose derivatives for treating bacterial infections. WO/2013/134415. 2013.
   Google Scholar
• Bennani YL, Liu B. Mannose derivatives for treating bacterial infections. WO/2014/055474. 2014.
   Google Scholar
• Dietrich E, Poisson C, Gallant M, et al. Mannoside derivatives for treating bacterial infections. WO2014/165107A2. 2014.
   Google Scholar
• Schönemann W, Kleeb S, Dätwyler P, et al. Prodruggability of carbohydrates – oral FimH antagonists. Can J Chem. 2016;94(11):909–919.
   PubMed Web of Science ®Google Scholar
• Kleeb S, Jiang X, Frei P, et al. FimH antagonists: phosphate prodrugs improve oral bioavailability. J Med Chem. 2016;59(7):3163–3182.
   PubMed Web of Science ®Google Scholar
• Lee RT, Lee YC. Affinity enhancement by multivalent lectin-carbohydrate interaction. Glycoconj J. 2000;17:543–551.
   PubMed Web of Science ®Google Scholar
• Nagahori N, Lee RT, Nishimura S-I, et al. Inhibition of adhesion of type 1 fimbriated Escherichia coli to highly mannosylated ligands. Chembiochem. 2002;3:836–844.
   PubMed Web of Science ®Google Scholar
• Papadopoulos A, Shiao TC, Roy R. Diazo transfer and click chemistry in the solid phase syntheses of lysine-based glycodendrimers as antagonists against Escherichia coli FimH. Mol Pharm. 2012;9:394–403.
   PubMed Web of Science ®Google Scholar
• Chalopin T, Brissonnet Y, Sivignon A, et al. Inhibition profiles of mono- and polyvalent FimH antagonists against 10 different Escherichia coli strains. Org Biomol Chem. 2015;13:11369–11375.
   PubMed Web of Science ®Google Scholar
• Yan X, Sivignon A, Yamakawa N, et al. Glycopolymers as antiadhesives of E. coli strains inducing inflammatory bowel diseases. Biomacromolecules. 2015;16:1827–1836.
   PubMed Web of Science ®Google Scholar
• Bouckaert J, Li Z, Xavier C, et al. Heptyl alpha-D-mannosides grafted on a beta-cyclodextrin core to interfere with Escherichia coli adhesion: an in vivo multivalent effect. Chemistry. 2013;19(24):7847–7855.
   PubMed Web of Science ®Google Scholar
• Gouin SG, Wellens A, Bouckaert J, et al. Synthetic multimeric heptyl mannosides as potent antiadhesives of uropathogenic Escherichia coli. ChemMedChem. 2009;4(5):749–755.
   PubMed Web of Science ®Google Scholar
• Yan X, Sivignon A, Barnich N, et al. A library of heptyl mannose-functionalized copolymers with distinct compositions, microstructures and neighboring non-sugar motifs as potent antiadhesives of type 1 piliated E. Coli Polym Chem. 2016;7:2674–2683.
   Web of Science ®Google Scholar
• Almant M, Moreau V, Kovensky J, et al. Clustering of Escherichia coli type-1 fimbrial adhesins by using multimeric heptyl a-D-mannoside probes with a carbohydrate core. Chem Eur J. 2011;17:10029–10038.
   PubMed Web of Science ®Google Scholar
• Lindhorst TK, Kieburg C, Krallmann-Wenzel U. Inhibition of the type 1 fimbriae-mediated adhesion of Escherichia coli to erythrocytes by multiantennary alpha-mannosyl clusters: the effect of multivalency. Glycoconj J. 1998;15(6):605–613.
   PubMed Web of Science ®Google Scholar
• Kötter S, Krallmann-Wenzel U, Ehlers S, et al. Multivalent ligands for the mannose-specific lectin on type 1 fimbriae of Escherichia coli: syntheses and testing of trivalent a-D-mannoside clusters. J Chem Soc Perkin Trans I. 1998;14:2193–2200.
   Google Scholar
• Schierholt A, Hartmann M, Lindhorst TK. Bi- and trivalent glycopeptide mannopyranosides as inhibitors of type 1 fimbriae-mediated bacterial adhesion: variation of valency, aglycon and scaffolding. Carb Res. 2011;346:1519–1526.
   PubMed Web of Science ®Google Scholar
• Barras A, Martin FA, Bande O, et al. Glycan-functionalized diamond nanoparticles as potent E. coli anti-adhesives. Nanoscale. 2013;5:2307–2316.
   PubMed Web of Science ®Google Scholar
• Durka M, Buffet K, Iehl J, et al. The functional valency of dodecamannosylated fullerenes with Escherichia coli FimH – towards novel bacterial antiadhesivesw. Chem Commun. 2011;47:1321–1323.
   PubMed Web of Science ®Google Scholar
• Touaibia M, Wellens A, Shiao TC, et al. Mannosylated G(0) dendrimers with nanomolar affinities to Escherichia coli FimH. ChemMedChem. 2007;2(8):1190–1201.
   PubMed Web of Science ®Google Scholar
• Sattin S, Bernardi A. Glycoconjugates and glycomimetics as microbial anti-adhesives. Trends Biotechnol. 2016;34(6):483–495.
   PubMed Web of Science ®Google Scholar
• Cecioni S, Imberty A, Vidal S. Glycomimetics versus multivalent glycoconjugates for the design of high affinity lectin ligands. Chem Rev. 2015;115(1):525–561.
   PubMed Web of Science ®Google Scholar
• Ramtohul YK, Das SK, Cadilhac C, et al. Mannose derivatives for treating bacterial infections. WO/2014/100158. 2014.
   Google Scholar